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New and Noteworthy: Long noncoding RNA (lncRNA) biology represents an exciting new field with 
implications in gene regulation. This field has only recently been investigated in the pathogenesis 
of ulcerative colitis. By utilizing high-throughput technologies on clinical samples, a lncRNA 
signature was generated and the lncRNA IFNG-AS1 was shown to regulate the important 
inflammatory cytokine interferon-γ. This work represents one of the first mechanistic studies of 
lncRNA biology in inflammatory bowel disease. 
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Abstract: 
 
High-throughput technologies revealed new categories of genes, including the long noncoding 
RNAs (lncRNAs), involved in the pathogenesis of human disease; however, the role of lncRNAs in 
the ulcerative colitis (UC) has not been evaluated. Gene expression profiling was used to develop 
lncRNA signatures in UC samples. Jurkat T cells were activated by PMA/ionomycin subsequently 
interferon-γ (IFNG) and tumor necrosis factor (TNF)-α protein levels were assessed by ELISA. Anti-
sense molecules were designed to block IFNG-AS1 expression. A unique set of lncRNAs was 
differentially expressed between UC and control samples. Of these, IFNG-AS1 was among the 
highest statistically significant lncRNAs (fold change: 5.27, P value: 7.07E-06). Bioinformatic 
analysis showed that IFNG-AS1 was associated with the IBD susceptibility loci SNP rs7134599 
and its genomic location is adjacent to the inflammatory cytokine IFNG. In mouse models of colitis, 
active colitis samples had increased colonic expression of this lncRNA. Utilizing the Jurkat T cell 
model, we found IFNG-AS1 to positively regulate IFNG expression. Novel lncRNA signatures 
differentiate UC patients with active disease, patients in remission, and control subjects. A subset 
of these lncRNAs was found to be associated with the clinically validated IBD susceptibility loci. 
IFNG-AS1 was one of these differentially expressed lncRNAs in UC patients and found to regulate 
the key inflammatory cytokine, IFNG, in CD4 T cells. Taking these findings together, our study 
revealed novel lncRNA signatures deregulated in UC and identified IFNG-AS1 as a novel regulator 
of IFNG inflammatory responses, suggesting the potential importance of noncoding RNA 
mechanisms on regulation of inflammatory bowel disease-related inflammatory responses. 
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Introduction 
 
INFLAMMATORY BOWEL DISEASES (IBDs) are common gastrointestinal disorders that are 
clinically comprised of ulcerative colitis (UC) and Crohn’s disease (CD) (14, 24). These diseases 
have a devastating toll on a patient’s morbidity and quality of life (27). The etiology of IBD, however, 
still remains elusive. Studies have shown that IBD may result from an inappropriate inflammatory 
response to intestinal microbes and foreign antigens in genetically susceptible hosts (8, 40). Key 
mediators of this inflammatory process such as TNF-α, IL-23, IL-12, and interferon-γ (IFNG) have 
been implicated in the pathogenesis of UC (1, 6, 10, 20, 25, 26). Therapies directed against these 
cytokines have been relatively successful in treating UC symptoms; however, a subpopulation of 
patients may fail to respond to these treatments (32, 33, 35). In addition to these cytokines, 
researchers have also focused on the genetic underpinnings of the disease. Familial clustering and 
twin studies have shown a role for genetic factors for UC (3, 14). Indeed, meta-analyses of multiple 
genome-wide association studies have implicated 163 genetic loci in both CD and UC pathogenesis 
(14). However, the mechanisms of action for many of the genes in close association with these loci 
have yet to be determined.  
 
The IBD susceptibility loci point to key genomic positions and highlight areas of the genome for 
further mechanistic studies. In addition to the associated protein-coding transcripts previously 
reported, noncoding transcripts may be associated with these loci. Recently, investigators have 
begun to address the noncoding transcripts and their role in disease pathogenesis. One such 
category of noncoding transcript are the long noncoding RNAs (lncRNAs) (21). The central dogma, 
wherein “DNA makes RNA makes protein,” has long relegated RNA as an intermediary between 
gene and protein. Recent research has challenged the notion that the noncoding RNAs are 
innocent bystanders and may indeed be critical to gene regulation (30, 31). Long noncoding RNAs 
are defined as sequences of greater than 200 nucleotides in length. They can express introns and 
exons, which can be alternatively spliced and generally lack open reading frames for protein 
translation (29). lncRNAs appear to have a diverse set of functions in chromatin remodeling, 
telomere activity, and subcellular structural organization (4). They can mediate epigenetic changes 
by recruiting chromatin-remodeling complexes to specific loci in the genome. As an example, the 
lncRNA HOTAIR has been implicated in inducing a repressive chromatin state by recruiting the 
Polycomb chromatin remodeling complex PRC2 (12). In addition, lncRNAs can regulate 
transcription by altering RNA polymerase II activity and thereby influence promoter activation (30). 
Finally, lncRNAs have also been implicated in various steps in the posttranscriptional processing 
of messenger RNAs, including splicing, editing, transport, translation, and degradation (21).  
 
Based on these above findings, it has been suggested that noncoding RNAs play a role in the 
pathogenesis of UC (15, 16, 28). In addition, lncRNAs have been shown to participate in multiple 
inflammatory processes and contribute to the pathogenesis of autoimmune and immune-related 
disorders; however, their role in UC has yet to be fully determined (2, 13, 18, 23). To this end, we 
have profiled the expression of both coding and noncoding transcripts in UC patients. By comparing 
their expression to those of control patients, we have identified a set of differentially expressed 
lncRNAs in adult UC patients. To evaluate the relationship of this set of lncRNAs with known IBD 
genomic alterations, we compared the chromosomal location of the lncRNAs with those of the IBD 
susceptibility loci. The lncRNA IFNG-AS1 was associated with the IBD susceptibility loci SNP 
rs7134599 and is in close proximity to the inflammatory cytokine IFNG. It was found to be among 
the most statistically significant differentially expressed lncRNAs. Given the close proximity to IFNG 
within the human genome, we investigated its cellular mechanism of action and found a positive 
regulatory mechanism between IFNG-AS1 and IFNG expression. 
 
Materials and Methods 
 
Human tissue collection and RNA extraction 
 
Colonic tissues were obtained from two sources. For the microarray analysis, RNA extracted from 
colonic surgical samples were obtained from Origene. A total of 50 anonymized samples, 19 for 
the initial profiling experiment and 31 for the validation cohort, were included in this study. For the 
profiling experiment, 7 control patients, 8 UC-active (UCA), and 4 UC-inactive (UCI) were collected. 
Diagnoses were confirmed by an independent set of pathologists associated with Origene. The 
samples were obtained through institutional review board (IRB) protocols and with documented 
patient consent, all from accredited U.S.-based medical institutions (www.origene.com). A second 
set of colonic samples was obtained from colonic surgeries performed at Cedars-Sinai Medical 
Center, Los Angeles, CA. These samples were collected under an IRB-approved protocol. Patients 
that participated in the IRB tissue recruitment were undergoing colonic resections as part of their 
regular medical care. A total of 31 anonymized patient samples were included in this part of the 
study, 16 control patients and 15 UC patients. A segment of the colon resection was flash frozen 
in liquid nitrogen and stored at -80°C. The diagnoses were confirmed on histopathology. Available 
patient information is summarized in Table 1. 
 
RNA extraction 
 
Total RNA was extracted from frozen colonic tissues and cells in culture using TRIzol (Qiagen, 
Valencia, CA; cat. no. 79306) and miRNeasy Mini Kit (Qiagen; cat. no. 217004) following the 
product instructions and utilizing DNase I digestion (cat. no. 79254). RNA was stored at _80°C and 
measured with a Nano-Drop 1000 Spectrophotometer (Thermo Scientific). The integrity of the RNA 
submitted for microarray analysis was assessed with either the Agilent Bioanalyzer RNA 6000 
LabChip kit (Agilent Technologies) or gel analysis. 
 
Microarray analysis for coding and non-coding transcripts 
 
For microarray analysis, the RNA samples were submitted to Arraystar for coding and noncoding 
RNA expression profiling. An Agilent Array platform was employed. The sample preparation and 
microarray hybridization were performed based on the manufacturer’s standard protocols with 
minor modifications. Briefly, mRNA was purified from total RNA after removal of rRNA (mRNA-
ONLY Eukaryotic mRNA Isolation Kit, Epicentre). Then, each sample was amplified and transcribed 
into fluorescent cRNA along the entire length of the transcripts without 3’ bias utilizing a random 
priming method (Arraystar Flash RNA Labeling Kit, Arraystar). The labeled cRNAs were hybridized 
onto the Human LncRNA Array v3.0 (8 X 60 K, Arraystar). After slides were washed, the arrays 
were scanned by the Agilent Scanner G2505C. 
 
Agilent Feature Extraction software (version 11.0.1.1) was used to analyze acquired array images. 
Quantile normalization and subsequent data processing were performed using the GeneSpring GX 
v12.1 software package (Agilent Technologies). After quantile normalization of the raw data, 
lncRNAs and mRNAs that at least 19 samples have flags in Present or Marginal (“All Targets 
Value”) were chosen for further data analysis. Differentially expressed lncRNAs and mRNAs were 
identified using Student’s t-test between two groups with a fold change cut-off >2 and P < 0.05. 
Pathway analysis and GO analysis were applied to determine the roles of these differentially 
expressed mRNAs played in these biological pathways or GO terms. Finally, Hierarchical 
Clustering was performed to show the distinguishable lncRNAs and mRNAs expression patterns 
among samples. 
 
The data discussed in this publication have been deposited in NCBI’s Gene Expression Omnibus 
(9) and are accessible through GEO Series accession number GSE77013. 
 
Quantitative-Real-time PCR for lncRNA and mRNA 
 
To analyze human gene expression, 500 ng of RNA was converted to Cdna using iScript cDNA 
synthesis kit (Bio-Rad; cat. no. 1708891). Real-time PCR was performed in triplicate using the 
SYBR Green mastermix (Bio-Rad; cat. no. 203450). qPCR primers were designed for the 
reference genes ACTIN and GAPDH, as well as IFNG-AS1, and IFNG. The SYBR-Green primers 
were ordered from Integrated DNA Technologies. The sequences are ACTIN-F: 5’-
cccagcacaatgaagatcaa-3’; ACTIN-R: 5’-acatctgctggaaggtggac-3’; GAPDH-F: 5’-
atgttcgtcatgggtgtgaa-3’; GAPDH-R: 5’-ggtgctaagcagttggtggt-3’; IFNG-AS1-F: 5’-
tgcctaggtgctctctgatg-3’; IFNG-AS1-R: 5’-ggcacaacccatggaagac-3’; IFNG-F: 5’-
gagtgtggagaccatcaagga-3’; IFNG-R: 5’-gtattgctttgcgttggaca-3’. The qPCRs were performed in a 
CFX384 Real Time PCR detection system (Bio-Rad). For gene expression of mouse genes 18S 
and Tmevpg1, TaqMan master mix (Applied Biosystems; cat. no. 4352042) was used and primers 
were ordered from Applied Biosystems (18S:Mm03928990_g1; Tmevpg1: Mm01161206_m1). 
 
Cell culture 
 
Jurkat CD4 T cells were generously provided by Dr. Otto Yang’s laboratory at UCLA. The cells 
were grown in RPMI+10%FBS+1% penicillin+1% streptomycin. Experiments were performed in 
24-well plates with 1 million cells plated in 1 ml of media. Activation of T cells was achieved by 6 h 
incubation at 37°C with phorbol-12-myristate-13-acetate (PMA) at a final concentration 
of 50 ng/ml and ionomycin at 1 µM concentration (PMA: Sigma-Aldrich; cat. no. P8139. Ionomycin: 
Sigma-Aldrich; cat. no. I3909). 
 
Peripheral mononuclear blood cells were obtained from blood draws at Cedars-Sinai Medical 
Center, Los Angeles, CA. The samples were obtained from control patients under the IRB no. 
23705. CD4 cells were isolated using the EasySep Human CD4+ T cell enrichment kit (Stemcell; 
cat. no. 19052). 
 
Knockdown and overexpression of lncRNA IFNG-AS1 
 
Reductions in IFNG-AS1 lncRNA expression were achieved using two custom-made siRNA 
constructs: siIFNG-AS1#1 sense, caaucuuaaggauacagaatt; siIFNG-AS1#2 sense, 
caaugcauuuauuaauucutt (Ambion). siRNA control was transfected for comparison (Ambion; cat. 
no. AM4613). Transfections were performed using Lipofectamine RNAiMax (Invitrogen; cat. no. 
13778-075) following the product instructions. Briefly, 5 µl of a 20 µM concentration of siRNA was 
mixed with 7.5 µl of Lipofectamine RNAiMax in 200 µl of Optimem media (Thermo Scientific; cat. 
no. 31985-062). The sample was incubated for 15 min and then added to 1 million Jurkat cells for 
24 h. Overexpression of the lncRNA was achieved by transfecting 4 µg of pCMV6-AC-IRES 
expression vector with IFNG-AS1 (Blue Heron). Control cells were transfected with the expression 
vector alone without insert. 
 
Protein analysis 
 
IFNG protein production was quantified using the Quantikine ELISA (R&D Systems; cat. no. 
DIF50). TNF-α protein production was assayed using the Milliplex Human High Sensitivity T cell 
Magnetic Bed Panel (Millipore; cat. no. HSTCMAG28SPMX13). Jurkat cells were grown in 24-well 
plates in 1 ml of volume. The cells were activated with PMA/ionomycin for 6 h and medium was 
collected 24 h after activation. The medium was centrifuged to remove excess cells. Manufacturer’s 
instructions were followed for quantification of protein using both kits. The quantity of protein 
expression was normalized to cell numbers at the time of collection. 
 
Mouse models of colitis 
 
Colitis was induced in mice via trinitrobenzenesulfonic acid (TNBS) treatment with modifications of 
previously described protocols (17). All animal studies were approved by the IACUC. Total RNA 
from the colonic tissues of the TNBS model was purified by use of the miReasy Mini Kit (Qiagen). 
Tissue sections were scored for histopathology analyses in a double-blinded manner, as previously 
reported (17). Animals were maintained at University of California-Los Angeles animal research 
facility and received standard pelleted chow and water ad libitum. The 6- to 8-wk-old male 
C57BL/6J mice (n = 8 per group) received a 50µl intracolonic injection of 40 mg/kg TNBS (Fluka) 
in 30% ethanol, using a 1-ml syringe (Becton Dickinson) fitted with a polyethylene cannula 
(Intramedic PE-20 tubing). The control groups were injected with 50 µl of 30% ethanol alone into 
the colon. The mice were held head down for 1 min after the enema administration to ensure the 
containment of the TNBS solution into the colon. The colons were fixed in 10% buffered formalin 
for histological analysis. Paraffin sections were stained with hematoxylin/eosin. 
 
IL10-/- C57BL/6 male (n = 8) and female (n = 8) mice were purchased from Jackson Laboratories 
(Bar Harbor, ME). Animals were kept under specific pathogen-free conditions and fed a standard 
diet and water ad libitum, under the approval by the institutional animal care and use committee 
(IACUC) at the Department of Veteran Affairs. Mice were weighed weekly and monitored for 
appearance of diarrhea and blood in the stools. Mice that developed severe rectal prolapse that 
was evident at all times were euthanized. Control mice were of the same background and 
euthanized at the same age. After euthanasia, the entire colon was excised and a portion of the 
proximal and distal colon was fixed in 10% buffered formalin for histological analysis. Paraffin 
sections were stained with hematoxylin/eosin. 
 
Experimental statistical analysis 
 
The Student’s t-test for two-group comparisons was performed to determine any statistically 
significant differences between the experimental groups. P < 0.05 was considered statistically 
significant. All results are expressed as means ± standard error on the mean. 
 
Results 
 
lncRNA signatures in UC colonic tissues.  
 
Clinical samples from a total of 19 patients consisting of colon resections from 8 UCA, 4 UCI, and 
7 control patients (Table 1), were used to perform lncRNA expression profiling analysis. The 
lncRNA expression profiling was performed using the Arraystar lncRNA microarray V3.0, which 
consists of ~30,600 lncRNAs. This analysis (>2-fold and P < 0.05) revealed that there were 1,931 
differentially expressed lncRNAs between UCA and control, while 1,361 lcnRNAs were differentially 
expressed between UCA and UCI colonic tissues (Figs. 1A and 2). Furthermore, 287 lncRNAs 
were found to be differentially expressed in UCI relative to control tissues (Fig. 2).   
 
A focus was placed on the comparison between UCA vs. control samples due to the robust 
statistical differences seen between these groups as well as access to a separate cohort of UC and 
control samples for validation studies. As a representative sample of these lncRNAs, Fig. 1, B and 
C demonstrates the top 15 most statistically significant upregulated and 15 downregulated lncRNAs 
differentially expressed between the UCA and control samples. As shown, the expression of these 
30 lncRNAs enables the clustering of the UCA samples away from the control samples, indicating 
that these IBD samples express a unique lncRNA expression signature that is distinct from control 
samples. Figure 1C identifies the 30 differentially expressed lncRNAs and shows the range of 
expression changes from over 20-fold upregulated to over 20-fold downregulated between the UCA 
and control patients. These results demonstrate that lncRNAs are significantly differentially 
expressed between UCA samples and controls and that the identity of the majority of these 
differentially expressed lncRNAs is unique between these comparisons. Taken together, these 
analyses show novel lncRNA signatures that were deregulated between UCA, UCI, and control 
colonic tissues. 
 
Differentially expressed lncRNAs are associated with known IBD loci.  
 
The list of lncRNAs differentially expressed in UCA samples compared with control samples spans 
the human genome. Previous research has identified 163 distinct single nucleotide polymorphism 
(SNP) loci as IBD susceptibility loci (14). A comparison of the chromosomal locations was per 
formed between the known IBD susceptibility loci and a list of lncRNAs differentially expressed in 
IBD samples. A list of lncRNAs was generated to compare the common differentially expressed 
lncRNAs between the UCA samples and the controls as well as the UCA and the inactive UC 
samples. This comparison was performed to assess for lncRNAs that were associated with active 
inflammation in UC samples. The analysis revealed that, of the 767 lncRNAs evaluated, only 31 
lncRNAs were found to be within 250 kilobases from the IBD loci (Fig. 3). The 250-kb distance was 
selected based on the analysis performed by Jostins et al. (14) where a locus was defined as at 
500-kb region with the SNP at its center. This comparison demonstrates that a portion of the 
lncRNAs identified as differentially expressed transcripts between IBD samples and control 
samples are closely associated with clinically validated IBD susceptibility loci. 
 
Validating lncRNA expression in a second cohort of UC patient samples.  
 
The lncRNA expression differences seen on the microarray analysis showed robust expression 
changes between the comparison groups. To validate these findings, a separate second cohort of 
UC samples was assayed for lncRNA expression. The samples consisted of 15 UCA samples and 
16 control colonic biopsy samples (Table 2). Total RNA from these samples was extracted and the 
level of expression for a select number of lncRNAs was performed using quantitative real-time 
polymerase chain reaction (qRT-PCR). We chose to validate the lncRNAs that were associated 
with the IBD susceptibility loci and were among the most statistically significant differentially 
expressed lncRNAs (Fig. 3). The lncRNAs RP11-81H14.2 and IFNG-AS1 were selected for 
validation (Fig. 4, A and B). RP11-81H14.2 expression analysis did not reveal a statistically 
significant difference between UC and control samples (Fig. 4D). IFNG-AS1, however, was found 
to be statistically different between the two sample cohorts and was chosen as a lncRNA of interest 
for further analysis (Fig. 4C). 
 
lncRNA-associated gene pathway analysis.  
 
To understand how changes in lncRNA expression may affect phenotypic changes in UC, an 
analysis of the changes in coding transcript expression was performed. It was hypothesized that 
changes in long noncoding RNA expression may affect coding transcript expression and as a result 
alter distinct gene pathways. To address this, the coding transcripts of each of the UC samples and 
control samples were assayed using the microarray platform from Arraystar. Nineteen patient 
samples were then divided into two groups: those expressing relatively high quantities of IFNG-
AS1 and those expressing relatively low amounts IFNG-AS1 as determined by their expression 
level on the microarray analysis (Fig. 5). In dividing the clinical samples into these two groups, the 
coding transcripts could then be assessed for differences in expression between the two groups. A 
threshold of a fold change of 1.5 upregulated and 2 downregulated was used to generate the coding 
transcript list. A total of 426 coding transcripts were differentially expressed using these cutoffs. By 
averaging the expression of the differentially expressed coding transcripts, a gene signature 
associated with relative IFNG-AS1 expression could be generated. Taking this list of differentially 
expressed coding transcripts, a bioinformatics gene pathway analysis was performed using 
Ingenuity Pathway Analysis software. Based on this analysis, several upstream regulators were 
shown to be activated in the IFNG-AS1 high samples including IFNG, IL1, IL6, and TNF-α (Fig. 5). 
Of particular interest, was the enhancement of IFNG signaling in the group that expresses higher 
levels of IFNG-AS1 as this had the lowest associated P value (Fig. 5). 
 
IFNG-AS1 expression in CD4 T cells.  
 
The lncRNA IFNGAS1 has previously been implicated in immune cell biology in both mouse and 
human studies (11, 39). In an attempt to identify a target cell for our selected lncRNA, we first 
examined peripheral CD4 T cells isolated from control patients. The expression of IFNG-AS1 was 
compared in the total peripheral mononuclear cells with the selected CD4 T subpopulation. Figure 
6A shows qRT-PCR data showing that CD4 T subpopulations have enriched expression of IFNG-
AS1 consistent with recently published data that IFNG-AS1 is expressed in the Th1 immune cells 
(39). 
 
Given these results, we chose to study the function of IFNG-AS1 using the Jurkat immune T cell 
model. Jurkat CD4 T cells can be activated via PMA and ionomycin stimulation and can be induced 
to secrete a variety of immune mediators such as IFNG and TNF-α (Fig. 6, B and C). Analyzing the 
RNA expression, PMA/ionomycin was found to induce IFNG-AS1 as well as IFNG and TNF-α (Fig. 
6D). Figure 7 highlights the time course of IFNG-AS1 and IFNG expression with IFNG-AS1 
reaching maximal induction 24 h after stimulation with PMA/ionomycin. 
 
IFNG-AS1 regulates IFNG expression at the RNA and protein level.  
 
Previous studies in mouse immune cells have suggested that Ifng-as1 can directly regulate the 
expression of its genomic neighbor, Ifng (11, 36). These studies reveal a pattern of histone 
methyltransferase recruitment to the Ifng promoter resulting in positive regulation of Ifng 
expression. We sought to show that the human ortholog, IFNG-AS1, could regulate IFNG 
production in a similar positive relationship. Using two siRNA constructs, we transiently transfected 
Jurkat T cells and assessed the expression of IFNG-AS1 and IFNG in the context of T cell activation 
via PMA/ionomycin. The induction of IFNG-AS1 was abrogated in both siRNAs by ~30-40% and 
resulted in reduced expression of IFNG RNA (Fig. 8, A and B). 
 
Protein expression was then analyzed with an IFNG-specific ELISA kit. IFNG protein levels were 
similarly abrogated when IFNG-AS1 expression was reduced (Fig. 8, C and D). 
 In addition to the knockdown studies, we generated an IFNG-AS1 overexpression construct and 
transiently transfected it to Jurkat T cells. Figure 9A demonstrates the level of overexpression of 
IFNG-AS1 achieved with this construct. When transfected into cells and induced with 
PMA/ionomycin, there was an increase in IFNG RNA levels as early as 4 h of PMA/ionomycin 
induction (Fig. 9B). Under these conditions, protein expression of IFNG was increased by an 
average of 45% (Fig. 9C). These data suggest that IFNG-AS1 has a direct relationship with the 
expression of IFNG within immune cells. 
 
Mouse models of colitis have increased Ifng-as1 levels.  
 
We then assessed whether colitis models would show a similar increase in the expression of the 
mouse ortholog Ifng-as1. We utilized two mouse models of colitis, the acute TNBS colitis model at 
48 h post-TNBS administration as well as the IL10 knockout mouse model of spontaneous colitis 
at age 12 wk. Colonic tissues were obtained from each mouse model and compared with controls. 
Expression of the lncRNA was then assessed by qRT-PCR. In both models, the mouse ortholog 
Ifng-as1 was found to be significantly elevated in the colitis setting compared with control (Fig. 10, 
A and B). These results are consistent with our human clinical data showing increased IFNG-AS1 
expression in colitis tissues. 
 
Discussion 
 
The diagnosis and treatment of IBD faces many challenges that can only be addressed by gaining 
a deeper understanding of the molecular mechanisms involved in the pathogenesis of the disease. 
Noncoding RNA biology has emerged as a new and potent form of gene regulation and has only 
recently began to be evaluated in IBD (7, 42). In the past year, Mirza et al. (22) performed the first 
transcriptomic profiling of lncRNAs in IBD patients and revealed hundreds of differentially 
expressed lncRNAs between UC, CD, and control patients. Additionally, Wu et al. (41) also 
reported a profiling analysis of lncRNAs differentially expressed in UC patients vs. controls. They 
evaluated over 60 patients with and without IBD and identified 455 lncRNAs that were differentially 
expressed. This group focused on one of the differentially expressed lncRNAs, BC012900, and 
showed that it can regulate epithelial cell apoptosis. Our IBD studies investigated differentially 
expressed lncRNAs among UC patients and in addition uncovered new potential mechanisms of 
action. Through a noncoding RNA expression analysis, we identified a set of lncRNAs that are 
differentially expressed between UC samples and controls. By focusing on those lncRNAs 
differentially expressed in UC patients, we then filtered our list to identify lncRNAs that were 
associated with the clinically validated IBD susceptibility loci. We were able to validate the 
differential expression of one of these lncRNAs, IFNG-AS1, with the use of a separate clinical 
cohort of colonic samples. Of note, Mirza et al. also found this lncRNA to be differentially expressed 
in their IBD patient samples, thereby providing further validation (22). Given its discovery on two 
independent analyses, IFNG-AS1 presents itself as an ideal candidate for further study. As one of 
the first mechanistic studies for lncRNAs in the IBD field, this work focused on IFNG-AS1. Future 
studies will be needed to investigate additional lncRNAs involved in IBD pathophysiology. 
 
IFNG-AS1 is a noncoding transcript located on chromosome 12 and adjacent to the IFNG gene. 
Prior studies have suggested that IFNG-AS1 can positively regulate IFNG expression; however, 
much of the data implies function from the mouse ortholog ifng-as1/NeST/tmevpg1. These previous 
investigations have shown that ifng-as1 is expressed in immune cells such as CD8 and CD4 T cells 
(5, 11, 37). The prior studies highlighted a mechanism wherein ifng-as1 recruits a subunit of 
MLL/SET1 H3K4 methyltransferase complex to the ifng promoter and lays down an activating 
histone methylation signal that promotes expression of ifng in mouse immune cells (11). This 
mechanism, however, has yet to be validated in the human context. Indeed, the human studies of 
IFNG-AS1 by Collier et al. (5) in the context of general immune cell biology and Wang et al. (39) in 
the context of Sjogren syndrome have shown expression of this noncoding transcript within CD4+ 
T cells. Our own studies show that a site of expression of IFNG-AS1 is within these CD4+ cells. 
Using knockdown and overexpression constructs in human T cells, we directly show that IFNG-
AS1 expression can positively regulate IFNG production. We suspect the relatively low abundance 
of the IFNG-AS1 transcript results in modest knockdown efficiencies seen in our model system. 
However, our data suggest that within immune cells there is a mechanistic link between the 
overexpression of this noncoding RNA in colitis samples and the production of a key inflammatory 
cytokine. In addition, lncRNAs have also been implicated in the stability of mRNA transcripts, 
thereby providing additional modes by which IFNG-AS1 could potentially regulate its targets (38). 
 
Through this work, we have identified a novel set of lncRNAs implicated in UC pathophysiology. 
Additional studies that are focused not only on IFNG-AS1 but also on the other noted lncRNAs 
presented in this work will be essential in expanding our knowledge of UC pathogenesis. lncRNAs 
have served as novel targets in preclinical studies from other fields of medicine such as cancer 
biology and may serve as important therapeutic targets in UC (19). Additionally, lncRNAs could 
also serve as important biomarkers with a range of uses (34). lncRNA biology is a nascent field in 
IBD and much work is needed to expand its potential applications. Future studies evaluating the 
effects of the IBD susceptibility SNPs on expression of lncRNAs will help to link the genotypic 
changes seen in patients with specific SNPs with expression changes in SNP-associated genes. 
Additionally, mouse models of colitis will need to be employed to better define the mechanisms for 
lncRNA biology. To this end, this study has identified that the murine ortholog ifgn-as1 is also 
overexpressed in the context of mouse models of colitis. This opens up additional avenues of 
research to carefully dissect other mechanisms of action for this noncoding RNA. The generation 
of ifng-as1 knockout and transgenic animals provides additional tools to investigate its function 
(11). All told, the lncRNA biology serves as an additional layer of gene regulation adding to the 
complexity of IBD pathophysiology but also providing new tissue-specific targets. 
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Figures 
Figure 1. 
 
 
 
Fig. 1. A: heat map representation of expression changes between UCA and control (Con) groups 
with a fold change greater than twofold and P value less than 0.05. B: heat map representation of 
the top 15 upregulated and 15 downregulated lncRNAs in the UCA vs. Con comparison. C: table 
shows the identity of the lncRNAs along with their associated P value, fold change, direction of 
regulation, RNA length, chromosomal location (chrom), strand location (strand), and transcriptional 
start (txStart) and end (txEnd) positions. Row min and max refer to the minimum and maximum 
expression levels. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. 
 
 
Fig. 2. Heat map representations of expression changes in lncRNA transcripts between UCA vs. 
UCI, UCI vs. Con. The number of differentially expression lncRNAs with a fold change cutoff of 2 
and a P value cutoff of 0.05. 
 
 
 
 
 
 
 
 
 
Figure 3. 
 
Fig. 3. Graphical representation of the overlap between the 163 IBD associated SNPs and the 
lncRNAs commonly differentially expressed between UCA vs. Con and UCA vs. UCI. The 
chromosomal location, lncRNA identity, associated SNP, and genomic distance from the SNPs are 
presented. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.  
 
Fig. 4. A and B: microarray expression data for the lncRNAs IFNG-AS1 and RP11-81H14.2 in the 
analysis comparing UCA vs. Con. C and D: qPCR expression for IFNG-AS1 and RP11- 81H14.2 
in the validation cohort (control N = 16, UC N = 15). ACTIN and GAPDH were used as control 
housekeeping genes. Relative expression was to the average expression in the control samples. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.  
 
Fig. 5. Expression of IFNG-AS1 based on microarray expression across all UC and control 
samples. Two groups were created showing relative high and low levels of IFNG-AS1. Bioinformatic 
analysis was performed on the associated coding transcript expression changes between the two 
groups. A list of upstream regulators found to be activated in the IFNG-AS1 high group are listed 
along with the predicated activation state and the associated P value. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. 
 
 
Fig. 6. A: qPCR expression of IFNG-AS1 and IFGN among CD4 cells and total PBMC (N = 4). B 
and C: Jurkat T cells activated with PMA/ionomycin for 6 h and cultured media collected after 24 h 
show inductions of IFNG and TNF-α protein, respectively. D: Jurkat T cells activated with 
PMA/ionomycin for 6 h; qPCR analysis of IFNG, IFNG-AS1, and TNF-α. *P value < 0.05, **P value 
< 0.01; n = 3.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.  
 
 
Fig. 7. qPCR expression for a time course evaluating the expression IFNG-AS1 and IFNG in Jurkat 
T cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 8.  
 
 
Fig. 8. A and B: qPCR analysis of Jurkat T cells treated with PMA/ionomycin for 6 h followed by a 
24-h recovery period. Cells were treated with 2 independent antisense siRNAs against IFNG-AS1 
(n = 3). C and D: protein analysis for IFNG was assessed by measuring the culture medium (n = 
3). The siRNAs refer to small interfering RNAs with siIFNG-AS1#1 and siIFNG-AS1#2 referring to 
two independent small interfering RNAs directed against IFNG-AS1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.  
 
Fig. 9. A: qPCR expression of Jurkat T cells transiently overexpressing IFNG-AS1. B: qPCR 
analysis of Jurkat T cells with and without transient transfection of an IFNG-AS1-overexpressing 
construct. Cells were activated with PMA/ionomycin for 4 h (n = 3). C: IFNG protein was measured 
from cultured media (n = 3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10.  
 
Fig. 10. A: Ifgn-as1 qPCR expression analysis. Whole colon samples from TNBS-treated animals 
vs. controls (N = 5) were assays for Ifng-as1 expression with actin as the control gene. B: Ifng-as1 
qPCR analysis from colon tissue derived from IL10 knockout animals compared with controls (N = 
4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tables 
 
Table 1. Patient information 
 
Sample Age Gender Location 
Con1 31 Male Colon 
Con2 45 Female colon 
Con3 26 Male Colon: sigmoid 
Con4 46 Male Colon 
Con5 50 Female Colon 
Con6 60 Female Colon 
Con7 56 Male Colon 
UCA1 30 Female Colon 
UCA2 56 Female Colon: left 
UCA3 26 Female Colon 
UCA4 46 Female Colon 
UCA5 29 Male Colon 
UCA6 24 Male Colon 
UCA7 45 Female Colon 
UCA8 26 Female Colon 
UCI1 31 Male Colon 
UCI2 71 Female Colon 
UCI3 51 Male Colon 
UCI4 33 Female Colon 
 
Table 2. Ulcerative colitis and control samples 
 
 
Control Disease Age Gender Pathology 
1 Diverticulosis n/a n/a n/a 
2 rectal cancer 50 F benign colonic tissue 
3 
rectal villous 
adenoma 68 F non-dysplastic mucosa 
4 
metastatic 
colon cancer 53 M colonic tissue with no histopathologic abnormality 
5 
colon cancer, 
cecum 76 F 
invasive adenocarcinoma of cecum with adajcent 
normal colon 
6 
colon cancer, 
rectum 70 M colonic adenocarcinoma with adjacent normal colon 
7 colon-normal n/a n/a n/a 
8 colon-normal n/a n/a n/a 
9 colon-normal n/a n/a n/a 
10 colon-normal n/a n/a n/a 
11 colon-normal n/a n/a n/a 
12 colon-normal 42 F 
foci of endometriosis, large intestine colon without 
significant change 
13 colon-normal n/a n/a n/a 
14 colon cancer n/a n/a n/a 
15 perforation n/a n/a n/a 
16 
vaginal 
prolapse n/a n/a n/a 
     
UC     
1 
ulcerative 
colitis 61 F 
moderate toseverely active ulcerative colitis, neg for 
dysplasia 
2 
ulcerative 
colitis 49 M 
chronic pancolitis with severe activity, extensive 
ulcerations 
3 
ulcerative 
colitis 52 F 
moderate to severe diffuse active pancolitis neg for 
dysplasia 
4 
ulcerative 
colitis 35 M 
moderate to severe activity, chronic pancolitis, neg 
dysplasia 
5 
ulcerative 
colitis 68 F severely active ulcerative colitis 
6 
ulcerative 
colitis 31 M chronic active colitis with foci of ulceration 
7 
ulcerative 
colitis 43 M n/a 
8 
ulcerative 
colitis 57 M 
chronic colitis with moderate to severe activity and 
extensive ulcerations 
9 
ulcerative 
colitis 39 F moderately active ulcerative colitis, neg dysplasia 
10 
ulcerative 
colitis 30 F colon with moderate chronic colitis, no dysplasia 
11 
ulcerative 
colitis 36 M 
chronic pancolitis with moderate to severe activity, 
ujlcration and inflammatory polyps 
12 
ulcerative 
colitis 49 F n/a 
13 
ulcerative 
colitis 64 M 
severe inflammatory bowel disease type 
indeterminate 
14 
ulcerative 
colitis 34 F Rectosigmoid, Involved 
15 
ulcerative 
colitis n/a n/a n/a 
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